Sign inJoin waitlistJoin the waitlist

Jonathan Moreira

Associate Professor, Feinberg School of Medicine · Feinberg School of Medicine

Credentials: · · · · · ·

History

Feinberg School of Medicine
Present

McGaw Medical Center of Northwestern University
Until 2016
Mayo Clinic College of Medicine and Science
Until 2012
Loyola University Stritch School of Medicine
2009

Research

Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls
Leukemia · 2013 · First of 13 authors · 101 citations
Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2020 · 87 citations
Targeted reduction of cholesterol uptake in cholesterol-addicted lymphoma cells blocks turnover of oxidized lipids to cause ferroptosis
Journal of Biological Chemistry · 2021 · 48 citations

Leo Gordon
9 papers
Reem Karmali
9 papers
Jane Winter
8 papers
Brian Hess
7 papers
Deborah Stephens
7 papers
Geoffrey Shouse
7 papers
Jonathon Cohen
7 papers
Lindsey Fitzgerald
7 papers · 4 as a resident
Narendranath Epperla
7 papers
Shuo Ma
7 papers
Tamara Moyo
7 papers
Thomas Ollila
7 papers

Grants

1/3: The Chicago Cancer Health Collaborative (ChicagoCHEC)
National Cancer Institute · U54
Project lead · $140K · Northwestern University
2015–2025

Clinical trials

Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Principal investigator · Withdrawn · Phase 2
Northwestern University
2020–2029
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Principal investigator · Completed · Phase 2
Northwestern University
2015–2024
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Study director · Recruiting · Phase 1
SciTech Development, Inc.
2023–2027
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Site PI · Recruiting · Phase 3
Corvus Pharmaceuticals, Inc.
2024–2028